BioArctic AB (publ) (BRCTF)
| Market Cap | 1.51B |
| Revenue (ttm) | 16.48M |
| Net Income (ttm) | -22.96M |
| Shares Out | n/a |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 16.61 |
| Previous Close | 16.61 |
| Day's Range | 16.61 - 16.61 |
| 52-Week Range | 12.94 - 27.66 |
| Beta | -0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About BioArctic AB
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheim... [Read more]
News
Leqembi® approved in Mexico
STOCKHOLM , Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) ...
Leqembi® launched in South Korea
STOCKHOLM , Nov. 27, 2024 /PRNewswire/ - BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. ...
CHMP issues positive recommendation for approval of lecanemab in the EU
STOCKHOLM , Nov. 14, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommen...
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
STOCKHOLM , Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs from...
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
STOCKHOLM , Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company's third quarter report for July - September 2024 on Thursday, November 14, 2024, at 08...
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
STOCKHOLM , Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer'...
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
STOCKHOLM , Oct. 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024, in co...
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
STOCKHOLM , Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Awar...
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
STOCKHOLM , Oct. 24, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeuti...
BioArctic AB: The David Against Goliath Of Solving Alzheimer's Disease
BioArctic's (BRCTF) Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate the stock a Buy.
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM , Oct. 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public stat...
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
STOCKHOLM , Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal o...
Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Au...
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been info...
Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
STOCKHOLM , Aug. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2024 on Thursday, August 29, 2024, at 08:00 a...
Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates
STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) ha...
Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024
STOCKHOLM , Aug. 1, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi® during the second quarter 2024, in c...
Long-term lecanemab data show increased patient benefit with maintained safety profile
STOCKHOLM , July 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented the latest findings for lecanemab (generic name, brand name: Leqembi®). Three-y...
Eisai will seek re-examination of CHMP opinion för lecanemab
STOCKHOLM , July 26, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will request re-examination of the Committee for Medicinal Products f...
CHMP has adopted a negative opinion on lecanemab for the EU
STOCKHOLM , July 26, 2024 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today communicated that it has adopted a negative opinion...
Long-term treatment data for lecanemab to be presented at AAIC 2024
STOCKHOLM , July 23, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that its partner Eisai will present the latest findings on lecanemab (generic name, brand name ...
Leqembi approved for the treatment of Alzheimer's disease in Israel
STOCKHOLM , July 12, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic name: lecanemab) has been approved for treatment of Alzh...
Leqembi approved for the treatment of Alzheimer's disease in Hong Kong
STOCKHOLM , July 11, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Department of Health in Hong Kong has approved Leqembi® (brand name in...
Leqembi® (lecanemab) launched in China
STOCKHOLM , June 28, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in China: "乐意保®", generic name: lecanemab) has...
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
STOCKHOLM , June 10, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supp...